Solorank.ai
Login

Cached score snapshot

US.INCY · Incyte

110分制 51.7/110；5D動能v2 8/50；排序分 59.7/160 · Incomplete inputs

Back to ranking Open volume snapshot
Ranking score 59.7/160
Main score 51.7/110
5D momentum v2 8/50
Rank #339
Setup grade F 24

Score breakdown

避免

Elevated twelvedata

Score and price trend

F 24 Elevated risk

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 05-12 08-05 08-21 09-03 09-17 $87.80$119.53$151.25 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.557 · anchors 120 +1.00% -1.48% / +4.37% 58.8% 2.5% Actual +2.27% · vs median +1.27% · inside 25-75 band
30D observation +11.24% +3.04% / +16.36% 86.3% 3.8% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +0.95% -1.47% / +3.64% 58.8% 2.5% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-05-12 → 2026-09-17 · 229 archived points · 3 Improving turn signal · 9 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 59.7
Display grade 避免
Model version cursor_18_27_news_v2_160
Main score 51.7/110 (避免)
5D momentum v2 8/50 (弱)
Score with momentum v2 59.7/160 (低排序)
Risk level Elevated

Audit trace

Full calculation detail

Calculation detail · 8 sections

Incomplete score

此 snapshot 已計出評分，但以下輸入仍不完整；缺失維度以 0 分處理，請留意 audit 明细。

  • VIX_MISSING: VIX market context is required for market environment scoring

Market inputs

Bar count 60
ma20 118.681
ma50 110.9026
close 118.38
prevClose 119.8
avgVolume20 1980641
volumeRatio 1.21
changePercent -1.19

Metrics snapshot

close 118.38
volume 2390313
changePercent -1.19

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 51.7/110
Main rating 避免
5D momentum v2 8/50
Score with momentum v2 59.7/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 5/5 · 優秀
Dimension score 5/5
Dimension grade 優秀

Sub-items

pbPoints 0.2
pePoints 0.5
epsPoints 0.75
roePoints 0.75
debtPoints 0.5
marginPoints 0.75
turnoverUsdM 282.9653
volumePoints 0.5
revenuePoints 0.75
dividendPoints 0
marketCapPoints 0.5

資金流 — 8.4/20 · 較差
Dimension score 8.4/20
Dimension grade 較差

Sub-items

cmfPoints 0.8
mfiPoints 3.2
obvPoints 1.6
vwapPoints 0.8

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.INCY
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 6.6/15 · 較差
Dimension score 6.6/15
Dimension grade 較差

Sub-items

vix

score 0

details

source twelvedata+fred
missing true
vixClose n/a

trend

score 3

details

qqq

ma20 700.462
ma50 714.6952
name QQQ
close 714.62
points 1

spy

ma20 749.2555
ma50 746.7324
name SPY
close 768.53
points 2
source twelvedata+fred
atrPct 3.8762
atrPoints 2
cciPoints 1.6
vixPoints 0
marketTrendPoints 3

催化劑 — 2/20 · 較差
Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 8
catalystCount 0
catalystPoints 2

風險管理 — 5.9/10 · 較差
Dimension score 5.9/10
Dimension grade 較差

Sub-items

position

score 1.3

details

atrPct 3.8762
turnoverUsdM 282.9653
liquidityPoints 0.6
volatilityPoints 0.7
rrPoints 1.4

stopLevels

symbol US.INCY
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 109.2028

strength_details

ma_score 1.5
atr_score 1
rsi_score 2
macd_score 1.5
volume_score 2
market_adjustment 1
risk_reward_ratio 1
stop_loss_percent 7.8
take_profit_price 127.8249
target_multiplier 1.9
technical_strength 1.63
take_profit_percent 8
positionPoints 1.3
stopLossPoints 1.2

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 7.7523
diversificationPoints 2

技術信號 — 17.8/30 · 較差
Dimension score 17.8/30
Dimension grade 較差

Sub-items

bbPoints 2.4
adxPoints 3
sarPoints 1.2
vcpPoints 2.7
macdPoints 2.4

vcpPayload

vcp_pass false
vcp_score 2.7
vcp_reason 波幅收縮(23.7%→15.3%)；跌縮量(近10日3日)；站上MA50；升放量(近10日3日)；Ready=Y；Confirm=N

vcp_metrics

up_days 4
vol_ref 1956533.3333
down_days 5
vcp_ready true
above_ma50 true
avg_vol_10 2347270
avg_vol_20 1928805
avg_vol_30 1956533.3333
range_pct_10 0.1528
range_pct_20 0.1862
range_pct_30 0.2375
up_expand_ok true
lookback_used 59
near_20d_high false
contraction_ok true
down_shrink_ok true
up_expand_days 3
breakout_20d_ok false
vol_ratio_10_30 1.1997
dist_to_20d_high 0.1072
down_shrink_days 3
breakout_level_20d 132.6
vcp_breakout_confirm false
contraction_ratio_10_30 0.6435
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction true
kdjAdxPoints 0.5
rsiKdjPoints 2.4
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 0
shortMacdPoints 0.4
volConfirmPoints 0
volumePointsTechnical 1.2

情緒分析 — 6/10 · 一般
Dimension score 6/10
Dimension grade 一般

Sub-items

sentiment

score 6

details

source finnhub_news_keyword_model
articleCount 8
negativeHits 0
positiveHits 4
sentimentScoreRaw 1.2

sentimentData

raw {"id":141124378,"url":"https://finnhub.io/api/news?id=2e9cdc845599ec8de38ca915bc2ee2ada5fb327446645dc572f0ce9a833e59b9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"REGN vs. INCY: Which Stock Is the Better Value Option?","category":"company","datetime":1785944402,"headline":"REGN or INCY: Which Is the Better Value Stock Right Now?"}, {"id":141089558,"url":"https://finnhub.io/api/news?id=d193e1a9da786dba927302825e1ac4e436b47d2a4ef395a053f2eb026d40287d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Incyte (INCY) is back in focus after the European Commission approved Opzelura cream for moderate atopic dermatitis in certain adults, shortly after the company reported second quarter results and raised full year sales guidance. See our latest analysis for Incyte. The recent European approval for Opzelura and the stronger second quarter results come after a period of firm momentum in Incyte’s stock, with a 90 day share price return of 23.33% and a 1 year total shareholder return of...","category":"company","datetime":1785618581,"headline":"Incyte (INCY) Won EU Approval For Opzelura, Has The Market Already Priced It In?"}, {"id":141089559,"url":"https://finnhub.io/api/news?id=66ee3d96f932a33253226f3002e3e870617e598368af7691a991672344718603","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Incyte stock has delivered a strong run over the last three years, yet the broader valuation checks suggest it may no longer stand out as a clear bargain at current levels. Incyte has returned 87.8% over the past three years, which puts fresh focus on whether recent gains already reflect much of the good news. Recent approvals for Opzelura in atopic dermatitis and new partnership activity can support confidence in future revenue, while execution risk around expanding treatments and...","category":"company","datetime":1785614991,"headline":"Incyte (INCY) Stock Trades Reasonable On Earnings While Returns Look Strong"}, {"id":141089087,"url":"https://finnhub.io/api/news?id=4cafa0c0c576492af58b5a037d3e4d674d60091cc75d218a9fff9032cba9f660","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"In July 2026, Incyte received European Commission approval for Opzelura (ruxolitinib) cream to treat moderate atopic dermatitis in adults who do not respond adequately to, or cannot use, topical corticosteroids and calcineurin inhibitors, supported by positive Phase 3 data showing improved symptoms, quality of life and tolerability. This second European indication for Opzelura, alongside strong Phase 3b TRuE-AD4 outcomes, highlights Incyte’s growing dermatology franchise and its ability to...","category":"company","datetime":1785611472,"headline":"European Opzelura Approval in Atopic Dermatitis Could Be A Game Changer For Incyte (INCY)"}, {"id":141088479,"url":"https://finnhub.io/api/news?id=817f6fcd57e34aec0ab49f7cd5b44a5e25bd5579e73d8284a3f8cfe53577ab60","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"European Commission approves Opzelura (ruxolitinib) cream as the first steroid free topical JAK inhibitor for adults with moderate atopic dermatitis in the EU. Decision is based on Phase 3b TRuE AD4 data in adult patients with mild to moderate atopic dermatitis. Approval expands Opzelura's use in Europe and adds a new dermatology revenue opportunity for Incyte. For investors following Incyte, ticker NasdaqGS:INCY, this EU approval adds a fresh piece of news around its dermatology efforts...","category":"company","datetime":1785604078,"headline":"Incyte (INCY) Wins EU Approval For Opzelura In Adult Moderate Atopic Dermatitis"}, {"id":141046508,"url":"https://finnhub.io/api/news?id=6f63228fc5636768c7177d6706a78488fb4357da7446b67f6d5006217d3645c2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Incyte Corp (INCY) reports a 38% increase in total revenue, raises full-year guidance, and highlights significant advancements in its diverse product pipeline.","category":"company","datetime":1785265310,"headline":"Incyte Corp (INCY) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and Strategic ..."}, {"id":141045188,"url":"https://finnhub.io/api/news?id=9b51439141c29da15f6773f0c3e11b7989e81beaf05eadbc1aee88f09c1c18eb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.","category":"company","datetime":1785256800,"headline":"INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised"}, {"id":141044114,"url":"https://finnhub.io/api/news?id=12a76a839b9588cb7b135e7669983aa7815af3ca9ca2dbfe5fcfa664b6ef1426","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.","category":"company","datetime":1785245406,"headline":"Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics"}
raw_source {"id":141137504,"url":"https://finnhub.io/api/news?id=5ba2cc11a9ecb49edc66612183fe45868379495b15bc40aff39523368206fff5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.","category":"company","datetime":1786029660,"headline":"Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised"}, {"id":141124378,"url":"https://finnhub.io/api/news?id=2e9cdc845599ec8de38ca915bc2ee2ada5fb327446645dc572f0ce9a833e59b9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"REGN vs. INCY: Which Stock Is the Better Value Option?","category":"company","datetime":1785944402,"headline":"REGN or INCY: Which Is the Better Value Stock Right Now?"}, {"id":141125130,"url":"https://finnhub.io/api/news?id=ec67b5cb9214019a7c398a6f91533f609baf347be1299b6c7d6517db16aaed99","image":"","source":"Benzinga","related":"INCY","summary":"Mizuho analyst Salim Syed maintains Incyte (NASDAQ:INCY) with a Outperform and raises the price target from $121 to $137.","category":"company","datetime":1785852726,"headline":"Mizuho Maintains Outperform on Incyte, Raises Price Target to $137"}, {"id":141099326,"url":"https://finnhub.io/api/news?id=cc2662e857815e4ce5bff63b03718501328f075fffcc39c614651be14387b757","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2156417320/image_2156417320.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"INCY","summary":"AbbVie Inc. stock fell 6.2% after a 52-week high despite strong Q2 earnings; Rinvoq and Elahere sales surged. Click for this ABBV earnings udpate.","category":"company","datetime":1785751531,"headline":"AbbVie: Strong Q2 And New Catalysts Keep Me Bullish"}, {"id":141099586,"url":"https://finnhub.io/api/news?id=2236694b532821ccd17ec78e8aa739f376a9517d1f738f8e47c88a2f4f048e45","image":"https://cdn.benzinga.com/files/images/story/2026/08/03/Warsaw--Poland--31-July-2024--Wola-Busin.jpg?width=2048&height=1536","source":"Benzinga","related":"INCY","summary":"Top Wall Street analysts changed their outlook on top names. Barclays raised DAR's target to $65, BTIG boosted SNOW's target to $340, and JP Morgan upgraded LYB to Overweight.","category":"company","datetime":1785744979,"headline":"Snowflake To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday"}, {"id":141103928,"url":"https://finnhub.io/api/news?id=c2efedbdc50b89967269d5ad051b03083f0c004678077351407ad8b011b50cca","image":"","source":"Benzinga","related":"INCY","summary":"Leerink Partners analyst Andrew Berens maintains Incyte (NASDAQ:INCY) with a Outperform and raises the price target from $131 to $155.","category":"company","datetime":1785739354,"headline":"Leerink Partners Maintains Outperform on Incyte, Raises Price Target to $155"}, {"id":141103929,"url":"https://finnhub.io/api/news?id=8fc96a3937efe7f6ca663d5460777c2b0f06f5cab3afbd580c097b489b24e7a3","image":"","source":"Benzinga","related":"INCY","summary":"HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $150 price target.","category":"company","datetime":1785737925,"headline":"HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target"}, {"id":141103930,"url":"https://finnhub.io/api/news?id=485fe4314e98cd1700421551c15cbb80275c7ebc3755e5fdc7bff0b5ada4863f","image":"","source":"Benzinga","related":"INCY","summary":"MinjuvI (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen listed on the Pharmaceutical Benefits Scheme","category":"company","datetime":1785724582,"headline":"Reported Sunday, Incyte's Minjuvi Plus Rituximab And Lenalidomide Now PBS-Funded In Australia, First New R/R Follicular Lymphoma Therapy Reimbursed In Nine Years"}, {"id":141089558,"url":"https://finnhub.io/api/news?id=d193e1a9da786dba927302825e1ac4e436b47d2a4ef395a053f2eb026d40287d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Incyte (INCY) is back in focus after the European Commission approved Opzelura cream for moderate atopic dermatitis in certain adults, shortly after the company reported second quarter results and raised full year sales guidance. See our latest analysis for Incyte. The recent European approval for Opzelura and the stronger second quarter results come after a period of firm momentum in Incyte’s stock, with a 90 day share price return of 23.33% and a 1 year total shareholder return of...","category":"company","datetime":1785618581,"headline":"Incyte (INCY) Won EU Approval For Opzelura, Has The Market Already Priced It In?"}, {"id":141089559,"url":"https://finnhub.io/api/news?id=66ee3d96f932a33253226f3002e3e870617e598368af7691a991672344718603","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Incyte stock has delivered a strong run over the last three years, yet the broader valuation checks suggest it may no longer stand out as a clear bargain at current levels. Incyte has returned 87.8% over the past three years, which puts fresh focus on whether recent gains already reflect much of the good news. Recent approvals for Opzelura in atopic dermatitis and new partnership activity can support confidence in future revenue, while execution risk around expanding treatments and...","category":"company","datetime":1785614991,"headline":"Incyte (INCY) Stock Trades Reasonable On Earnings While Returns Look Strong"}, {"id":141089087,"url":"https://finnhub.io/api/news?id=4cafa0c0c576492af58b5a037d3e4d674d60091cc75d218a9fff9032cba9f660","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"In July 2026, Incyte received European Commission approval for Opzelura (ruxolitinib) cream to treat moderate atopic dermatitis in adults who do not respond adequately to, or cannot use, topical corticosteroids and calcineurin inhibitors, supported by positive Phase 3 data showing improved symptoms, quality of life and tolerability. This second European indication for Opzelura, alongside strong Phase 3b TRuE-AD4 outcomes, highlights Incyte’s growing dermatology franchise and its ability to...","category":"company","datetime":1785611472,"headline":"European Opzelura Approval in Atopic Dermatitis Could Be A Game Changer For Incyte (INCY)"}, {"id":141088479,"url":"https://finnhub.io/api/news?id=817f6fcd57e34aec0ab49f7cd5b44a5e25bd5579e73d8284a3f8cfe53577ab60","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"European Commission approves Opzelura (ruxolitinib) cream as the first steroid free topical JAK inhibitor for adults with moderate atopic dermatitis in the EU. Decision is based on Phase 3b TRuE AD4 data in adult patients with mild to moderate atopic dermatitis. Approval expands Opzelura's use in Europe and adds a new dermatology revenue opportunity for Incyte. For investors following Incyte, ticker NasdaqGS:INCY, this EU approval adds a fresh piece of news around its dermatology efforts...","category":"company","datetime":1785604078,"headline":"Incyte (INCY) Wins EU Approval For Opzelura In Adult Moderate Atopic Dermatitis"}, {"id":141086380,"url":"https://finnhub.io/api/news?id=a1b1742c992e86e8d9ed9e79579e23316e166304fcfe86f582799192885bc109","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.","category":"company","datetime":1785571917,"headline":"1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds"}, {"id":141056000,"url":"https://finnhub.io/api/news?id=25bcacd240f3bfeeac2755d895eda5e1df2a34a1738e86b8bb28e50d7b71921a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"The European Commission on Wednesday approved Incyte’s Opzelura cream as the first steroid-free topical treatment of its kind for adults with moderate eczema who do not get enough relief from standard creams.","category":"company","datetime":1785345731,"headline":"Incyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod"}, {"id":141057549,"url":"https://finnhub.io/api/news?id=74e2a18e2341a38b90ab247eb729d4ca76f6125ef10ac31a2524925b0e83eec3","image":"","source":"Benzinga","related":"INCY","summary":"RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $99 to $109.","category":"company","datetime":1785332115,"headline":"RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $109"}, {"id":141057550,"url":"https://finnhub.io/api/news?id=40386d9cb4aac281a6b0481ca34deb27152a95af696e43543d3343140b79a456","image":"https://cdn.benzinga.com/files/images/story/2026/07/29/Konskie--Poland---December-08--2024-Incy.jpg?width=2048&height=1536","source":"Benzinga","related":"INCY","summary":"Incyte Corp. (INCY) reported strong Q2 results, raised full-year sales guidance. CEO cites sales growth, pipeline progress, and business development. Analysts maintain buy ratings with price target increases.","category":"company","datetime":1785322406,"headline":"Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results"}, {"id":141057551,"url":"https://finnhub.io/api/news?id=bc5ca8c81baad7c9f72efd5d2ea26272d756b81ce616c2718a93d4e8af4c07bc","image":"","source":"Benzinga","related":"INCY","summary":"Guggenheim maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $136 to $150.","category":"company","datetime":1785320483,"headline":"Guggenheim Maintains Buy on Incyte, Raises Price Target to $150"}, {"id":141052276,"url":"https://finnhub.io/api/news?id=1a077f383181680361593f4fc0cdfe88a9cc78b10e55fc46662e3e357a704820","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"WILMINGTON, Del., July 29, 2026--Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the EU for Adults with Moderate Atopic Dermatitis","category":"company","datetime":1785319200,"headline":"Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis"}, {"id":141057552,"url":"https://finnhub.io/api/news?id=5c418c9628fe19002024d6653630d9b9fee4635bde2599fcce60253b83268ed3","image":"","source":"Benzinga","related":"INCY","summary":"BMO Capital analyst Evan Seigerman maintains Incyte (NASDAQ:INCY) with a Market Perform and raises the price target from $112 to $130.","category":"company","datetime":1785318946,"headline":"BMO Capital Maintains Market Perform on Incyte, Raises Price Target to $130"}, {"id":141053819,"url":"https://finnhub.io/api/news?id=d2c922f03b1f56364c6cb0efc7927b30fcba8881b67cae6e586801e9d792f6b8","image":"https://cdn.benzinga.com/files/images/story/2026/07/29/Healthcare-stocks.jpg?width=2048&height=1536","source":"Benzinga","related":"INCY","summary":"RSI warning: 3 overbought health care stocks could be flashing a real warning to investors with high momentum trading preferences","category":"company","datetime":1785314722,"headline":"Top 3 Health Care Stocks That May Implode This Month"}, {"id":141057554,"url":"https://finnhub.io/api/news?id=f173421e6fdb09349bc9b98244ae8f6da6a4f51f094f121839ef819f0bdc7f4a","image":"","source":"Benzinga","related":"INCY","summary":"Barclays analyst Etzer Darout maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $134 to $139.","category":"company","datetime":1785313264,"headline":"Barclays Maintains Overweight on Incyte, Raises Price Target to $139"}, {"id":141057555,"url":"https://finnhub.io/api/news?id=15490808f6c716b8670ec8e4a3ac083f03234778ad32f16a672785d1ef10aeb7","image":"","source":"Benzinga","related":"INCY","summary":"HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $140 to $150.","category":"company","datetime":1785306378,"headline":"HC Wainwright & Co. Maintains Buy on Incyte, Raises Price Target to $150"}, {"id":141057556,"url":"https://finnhub.io/api/news?id=dd8bfd44f7f4c71f85276aabd63a2477ae821d094b6f0e3d8cd4a88bf11d6197","image":"","source":"Benzinga","related":"INCY","summary":"The European Commission approval is based on Phase 3b TRuE‑AD4 data which demonstrated that Opzelura® (ruxolitinib) cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment","category":"company","datetime":1785304963,"headline":"Incyte Says EC Approves Opzelura Cream For Treatment Of Moderate Atopic Dermatitis In Adult Patients"}, {"id":141046067,"url":"https://finnhub.io/api/news?id=28852786028f830f8c93415f5e5497f7948584b12d1d51d853db9c580c37e955","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"INCY","summary":"Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.","category":"company","datetime":1785265501,"headline":"Exploring the top movers within the S&P500 index during today's session."}, {"id":141046508,"url":"https://finnhub.io/api/news?id=6f63228fc5636768c7177d6706a78488fb4357da7446b67f6d5006217d3645c2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Incyte Corp (INCY) reports a 38% increase in total revenue, raises full-year guidance, and highlights significant advancements in its diverse product pipeline.","category":"company","datetime":1785265310,"headline":"Incyte Corp (INCY) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and Strategic ..."}, {"id":141044671,"url":"https://finnhub.io/api/news?id=60d82d912a0cbbf84300ba4e349dd2be3cc82511f788156598ee6f9cfa8ab719","image":"https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp","source":"ChartMill","related":"INCY","summary":"Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below.","category":"company","datetime":1785258300,"headline":"Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below."}, {"id":141045188,"url":"https://finnhub.io/api/news?id=9b51439141c29da15f6773f0c3e11b7989e81beaf05eadbc1aee88f09c1c18eb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.","category":"company","datetime":1785256800,"headline":"INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised"}, {"id":141048636,"url":"https://finnhub.io/api/news?id=108957862ddf2373a16785e6688d3ad7e0cb2a9cd5b6003f083b48a5bf45f5e1","image":"https://cdn.benzinga.com/files/images/story/2026/07/28/Konskie--Poland---December-08--2024-Incy.jpg?width=2048&height=1536","source":"Benzinga","related":"INCY","summary":"Incyte (INCY) Q2 earnings beat estimates with $1.67B revenue, $3.09 EPS. Full-year sales guidance raised. Shares rally to new 52-week high.","category":"company","datetime":1785251422,"headline":"Incyte Says It's No Longer A One-Drug Story"}, {"id":141045820,"url":"https://finnhub.io/api/news?id=6a737a4ae55d24ee85b70d55e05108fe48c0483ee293c4c3449d86ca61ec7390","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"INCY","summary":"2026-07-28. The following slide deck was published by Incyte Corporation in conjunction with their 2026 Q2 earnings call.","category":"company","datetime":1785249140,"headline":"Incyte Corporation 2026 Q2 - Results - Earnings Call Presentation"}, {"id":141044113,"url":"https://finnhub.io/api/news?id=525ea22bfc0aacfce1da10e0d3444dc997e7bc6a9a938e2bf465d99100229ba9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Incyte (NASDAQ:INCY) reported second-quarter 2026 net product sales of $1.49 billion, up 40% from a year earlier, supported by demand growth across its marketed portfolio and a one-time non-cash benefit tied to the resolution of a CMS matter involving OPZELURA. Excluding the $246 million one-time b","category":"company","datetime":1785247454,"headline":"Incyte Q2 Earnings Call Highlights"}, {"id":141044114,"url":"https://finnhub.io/api/news?id=12a76a839b9588cb7b135e7669983aa7815af3ca9ca2dbfe5fcfa664b6ef1426","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.","category":"company","datetime":1785245406,"headline":"Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics"}, {"id":141042794,"url":"https://finnhub.io/api/news?id=fbd9cd328e5d6e2a42fcc9224756b806eabc2ce57cecc5da3f7d9c4db3a3e37e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Incyte (NASDAQ:INCY) reported better-than-expected second-quarter earnings and revenue on Tuesday, although its shares edged lower in pre-market trading after the company issued full-year sales guidance that came in below analysts’ expectations. The biotechnology group delivered strong growth across its commercial portfolio, supported by higher sales from several key products and continued pipeline progress.","category":"company","datetime":1785245376,"headline":"Incyte Tops Second-Quarter Expectations but Shares Slip on Lower Revenue Outlook"}, {"id":141042029,"url":"https://finnhub.io/api/news?id=c96d09c019061ce7d6feed85e21a0c0f1efc7c1b939fc4a7215f66194fd03c5a","image":"https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_16_065e226ebd.webp","source":"ChartMill","related":"INCY","summary":"Incyte beat Q2 estimates but slashed full-year guidance and raised expenses on a $1.27B acquisition, sending shares down 31% pre-market.","category":"company","datetime":1785241400,"headline":"Incyte (NASDAQ:INCY): High Growth Stock Slides on Q2 Beat but Steep Guidance Cut"}, {"id":141044416,"url":"https://finnhub.io/api/news?id=0d4f33d7e5de25a063c9dd5083916e021be4ec9699b53a15cb53d71306169487","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"INCY","summary":"Incyte Corporation (INCY) Q2 2026 Earnings Call July 28, 2026 8:00 AM EDTCompany ParticipantsAlexis Smith - VP & Head of Investor RelationsWilliam Meury...","category":"company","datetime":1785241392,"headline":"Incyte Corporation (INCY) Q2 2026 Earnings Call Transcript"}, {"id":141042795,"url":"https://finnhub.io/api/news?id=3fcb7f376b8aeff1d961740a2084bb1f9106c89c8c86847feed2af8c200c0c8c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Incyte (INCY) delivered earnings and revenue surprises of +54.50% and +14.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?","category":"company","datetime":1785240902,"headline":"Incyte (INCY) Q2 Earnings and Revenues Top Estimates"}, {"id":141041896,"url":"https://finnhub.io/api/news?id=deb542f41aa7f434c46038cc10d4ee4c66e9da2a1fdb0bb664275f2f273c979d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 37.7% year on year to $1.67 billion. On the other hand, the company’s full-year revenue guidance of $5.20 billion at the midpoint came in 9.2% below analysts’ estimates. Its non-GAAP profit of $3.09 per share was 43.9% above analysts’ consensus estimates.","category":"company","datetime":1785238648,"headline":"Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q2 CY2026 But Full-Year Sales Guidance Misses Expectations Significantly"}, {"id":141048637,"url":"https://finnhub.io/api/news?id=fca5e3f6a42f39cc70236eb123ad64a4acd4353b60877406ffeff2a86ed0df57","image":"https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_2.jpg?width=2048&height=1536","source":"Benzinga","related":"INCY","summary":"In a new SEC filing on July 27, it was unveiled that Heeson, EVP at Incyte (NASDAQ:INCY), acquired stock options for 15,423 shares.\nWhat Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on","category":"company","datetime":1785236445,"headline":"A Noteworthy Decision By Lee Heeson As Acquires $130K In Incyte Stock Options"}, {"id":141048638,"url":"https://finnhub.io/api/news?id=021975f7161fbfbaa830a159bef61b90420ef6b1ff29263b4995686d0d8bec97","image":"https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_1.jpg?width=2048&height=1536","source":"Benzinga","related":"INCY","summary":"James Michael Morrissey, EVP at Incyte (NASDAQ:INCY), reported acquisition of company stock options on July 27, according to a new SEC filing.\nWhat Happened: Uncovered in a Form 4 filing on Monday with the U.S.","category":"company","datetime":1785236444,"headline":"James Michael Morrissey Expands Holdings With $54K Incyte Stock Options Acquisition"}, {"id":141041897,"url":"https://finnhub.io/api/news?id=32ab29909cba625ffb15085d0d5c96aeb1a13aba9148a5a5c07b9ef9e1684be5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"WILMINGTON, Del., July 28, 2026--Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates","category":"company","datetime":1785236400,"headline":"Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates"}, {"id":141042267,"url":"https://finnhub.io/api/news?id=8eb48457e30ed759574902fad91ecc34d75054fa92fff08f027b6ddf02e62c26","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1329696857/image_1329696857.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"INCY","summary":"Incyte Corporation stock hits a 52-week high on latarcibart and strong Opzelura/Zynyz sales, but valuation & Iclusig demand drive a Hold. Click for an INCY update.","category":"company","datetime":1785231217,"headline":"Incyte: From Buy To Hold After A 93% Rally (Rating Downgrade)"}, {"id":141045517,"url":"https://finnhub.io/api/news?id=0e144d572c44e6dd35db0b4ad9192f81b8967aff5437052626aaa80b900565f9","image":"https://cdn.benzinga.com/files/images/story/2026/07/28/Servicenow-Office-Building-At-Their-Head.jpg?width=2048&height=1536","source":"Benzinga","related":"INCY","summary":"ServiceNow shares rose 6.9% to settle at $105.56 during the session, while Meta shares fell 0.2% to close at $593.87 on Monday.","category":"company","datetime":1785226718,"headline":"ServiceNow, Meta, eBay And A Health Care Stock On CNBC’s ‘Final Trades’"}, {"id":141048640,"url":"https://finnhub.io/api/news?id=49a358e634e174f6a43f4be58a48b5abcc7cd8bc78e77527abf5ce0adf1233f0","image":"","source":"Benzinga","related":"INCY","summary":"Incyte (NASDAQ:INCY) reported quarterly earnings of $3.09 per share which beat the analyst consensus estimate of $2.12 by 45.75 percent. This is a 96.82 percent increase over earnings of $1.57 per share from the same","category":"company","datetime":1785222171,"headline":"Incyte Q2 Adj. EPS $3.09 Beats $2.12 Estimate, Sales $1.663B Beat $1.460B Estimate"}, {"id":141048641,"url":"https://finnhub.io/api/news?id=2464e6d7fb6f48df07bacaf57abaf7b834d6343bdac34e55985cb7be19debe3b","image":"","source":"Benzinga","related":"INCY","summary":"Incyte (NASDAQ:INCY) raises FY2026 sales outlook from $4.770 billion-$4.940 billion to $5.130 billion-$5.260 billion vs $5.712 billion estimate.","category":"company","datetime":1785222058,"headline":"Incyte Raises FY2026 Sales Guidance from $4.770B-$4.940B to $5.130B-$5.260B vs $5.712B Est"}, {"id":141031220,"url":"https://finnhub.io/api/news?id=2d9b5d3986d187fb5197c5ef9b0edab80e70e9a9efcc6abde9508b72f0a279da","image":"https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp","source":"ChartMill","related":"INCY","summary":"INCY stock shows a perfect technical breakout setup with a 10/10 Technical Rating and 9/10 Setup Quality, featuring a bull flag pattern and strong momentum.","category":"company","datetime":1785140441,"headline":"INCYTE CORP (NASDAQ:INCY) Exhibits Perfect Technical Breakout Setup with Strong Ratings"}, {"id":141030717,"url":"https://finnhub.io/api/news?id=ad4f54ff1118d2b454e581ed1dfde278d76cb2e6b8f5c0deb0f11f897d8b3228","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Tuesday before the bell. Here’s what to look for.","category":"company","datetime":1785126542,"headline":"What To Expect From Incyte’s (INCY) Q2 Earnings"}, {"id":141021094,"url":"https://finnhub.io/api/news?id=3dc13cfc64224bb859f64f02def1e1e27d7a4e954ab5830cfdac7e3136c8c299","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Incyte (NasdaqGS:INCY) reported full safety and efficacy results from its Phase 1/2 study of latarcibart, a once monthly subcutaneous therapy for von Willebrand disease. The company announced the acquisition of VGA039 (latarcibart) through the purchase of Vega Therapeutics to support further development. Latarcibart carries breakthrough, fast track, orphan drug, and rare pediatric disease designations. For investors tracking Incyte, this update sits at the intersection of rare disease drug...","category":"company","datetime":1785028292,"headline":"Incyte (INCY) Reports Full Latarcibart Data And Buys Vega Therapeutics"}, {"id":141007726,"url":"https://finnhub.io/api/news?id=05aeb953d4a880fc4fda1e7fcea9049fded33c60c04eb95d11f61b77c46633f7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"INCY heads into Q2 earnings with strong Jakafi demand, Opzelura momentum and rising royalties, fueling expectations for an earnings beat.","category":"company","datetime":1784903880,"headline":"Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner?"}, {"id":141004058,"url":"https://finnhub.io/api/news?id=c6d0f91d2a89e21ca5c3f4abc044cb229a668a9fb38d1b68174b1f2d89a4b18a","image":"https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp","source":"ChartMill","related":"INCY","summary":"INCY stock shows strong earnings acceleration with 304% EPS growth and a perfect technical rating of 10, offering a defined breakout entry above $118.53 for momentum investors.","category":"company","datetime":1784889636,"headline":"INCYTE CORP (NASDAQ:INCY) Screens as a High Growth Momentum Stock with a Breakout Setup"}, {"id":141008283,"url":"https://finnhub.io/api/news?id=a3c2f7a33f947eadc415691b2014909cd794a2fd6fde678f16f4a21b275753f3","image":"","source":"Benzinga","related":"INCY","summary":"JP Morgan analyst Jessica Fye maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $105 to $110.","category":"company","datetime":1784817699,"headline":"JP Morgan Maintains Neutral on Incyte, Raises Price Target to $110"}, {"id":141008284,"url":"https://finnhub.io/api/news?id=4fa3db6dad4d32f41a2fe234aa35c45d9af1dc13c079b1d15b07f323c67cd202","image":"","source":"Benzinga","related":"INCY","summary":"Morgan Stanley analyst Judah Frommer maintains Incyte (NASDAQ:INCY) with a Equal-Weight and raises the price target from $103 to $104.","category":"company","datetime":1784815340,"headline":"Morgan Stanley Maintains Equal-Weight on Incyte, Raises Price Target to $104"}, {"id":140983371,"url":"https://finnhub.io/api/news?id=246cd6e33abf5deef3bb65b29fdbc58a7be46dfa9b5832fd032d7466d9b44940","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"LENZ Therapeutics, Inc. (LENZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.","category":"company","datetime":1784728830,"headline":"Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline"}, {"id":140971589,"url":"https://finnhub.io/api/news?id=6e9cb60560ec50a9dc2a5e4ff31cabd7f9a7b79b6c11da15cec0d4eda37c4146","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, aiming to improve treatment convenience for patients.","category":"company","datetime":1784644680,"headline":"HALO Inks Deal With INCY to Support Cancer Therapy Development"}, {"id":140972028,"url":"https://finnhub.io/api/news?id=ea7c64df2412008d93ad36aeb06ea3400274c5b1bce9ff23162a508765035b15","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.","category":"company","datetime":1784642419,"headline":"Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth"}, {"id":140972899,"url":"https://finnhub.io/api/news?id=b5039eeb51094b56bb15c6fbd0589d8bb8cc90e6bad42f0e7c7cf28242d94726","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160060870/image_1160060870.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"INCY","summary":"Baker Brothers’ Q1 2026 13F: $17.42B biotech portfolio, top holdings & key buys/sells. Click here to read more.","category":"company","datetime":1784640414,"headline":"Tracking Baker Brothers Portfolio: Q1 2026 Update"}, {"id":140977013,"url":"https://finnhub.io/api/news?id=0ca787b8d9130278ed0e7cc63691221b1f3d4ac2546209e8729a89acb3a868c6","image":"","source":"Benzinga","related":"INCY","summary":"HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $140 price target.","category":"company","datetime":1784615425,"headline":"HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $140 Price Target"}, {"id":140961075,"url":"https://finnhub.io/api/news?id=cffda6abacbacb10f1ab1cfb04b69376d4da6bdf87dd29f22082c36c286acd31","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Halozyme Therapeutics (NASDAQ:HALO) has entered into a global collaboration and license agreement with Incyte (NASDAQ:INCY) to support the development of subcutaneous formulations of INCA033989, expanding the use of its ENHANZE® drug delivery technology into another partnered program. Key Investor TakeawaysHalozyme signed a global collaboration and license agreement with Incyte centered on ENHANZE® drug delivery technology.","category":"company","datetime":1784559763,"headline":"Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Development"}, {"id":140958865,"url":"https://finnhub.io/api/news?id=fe19aee917b682379e43eb92e51267d0b966c6a7e12e193fa0f4b1239dad3666","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Halozyme Therapeutics, Inc. (Nasdaq: HALO) (\"Halozyme\" or the \"Company\") today announced that it has entered into a global collaboration and license agreement with Incyte (Nasdaq: INCY) to evaluate additional subcutaneous formulations of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs), utilizing Halozyme's proprietary ENHANZE® drug delivery technology. The collaboration will focus on","category":"company","datetime":1784548800,"headline":"Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology"}, {"id":140958478,"url":"https://finnhub.io/api/news?id=cc6ec253511baccbdfea5ad1f5f444625c032d12536f4b0d04339169e1be0d6d","image":"https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp","source":"ChartMill","related":"INCY","summary":"Incyte Corp (INCY) offers a compelling value opportunity with strong profitability, near-zero debt, and a P/E of 15.76—well below the biotech industry average of 36.43. Despite slowing growth forecasts, its low valuation provides a solid margin of safety.","category":"company","datetime":1784546426,"headline":"Incyte Corp (NASDAQ:INCY) Shows Value Stock Strength With Strong Fundamentals and Low Valuation"}, {"id":140965151,"url":"https://finnhub.io/api/news?id=6e09676ee2faf44c563ffb6d43432f0a928562e1a85e9fbc345546cf2b476777","image":"","source":"Benzinga","related":"INCY","summary":"Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced that it has entered into a global collaboration and license agreement with Incyte (NASDAQ:INCY) to evaluate","category":"company","datetime":1784534503,"headline":"Halozyme Therapeutics Signs Agreement With Incyte To Mull Additional Subcutaneous Formulations Of INCA033989 Mutant Calreticulin-Targeted Monoclonal Antibody"}, {"id":140955778,"url":"https://finnhub.io/api/news?id=989fbbfabc0bbae37e46ab4bb57fb1e7723b8234cb8ccda6eb5366a42f05e17e","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2285994413/image_2285994413.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"INCY","summary":"Xencor (XNCR) stays a Strong Buy as XmAb819 and XmAb942 advance; key data due 2026–2027 and $542M cash extends runway—read the outlook now.","category":"company","datetime":1784493770,"headline":"Xencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim Data"}, {"id":140934672,"url":"https://finnhub.io/api/news?id=87e27eb69603b6ccc7a6a57a2d4741fe9b7d8c1349d5a887b8c1f5ef9659d186","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"WILMINGTON, Del., July 17, 2026--Incyte Data to Be Highlighted in Four Rapid Oral Presentations at ESMO 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers","category":"company","datetime":1784308200,"headline":"Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers"}, {"id":140935749,"url":"https://finnhub.io/api/news?id=bea42c5120469a8c954f17659495dd562c8902c0244836e35eb6837eb95f7ee1","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1196320934/image_1196320934.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"INCY","summary":"Incyte Corporation is a profitable, cash-generating biotech with a robust pipeline and a core revenue driver in Jakafi. Read more on INCY stock here.","category":"company","datetime":1784301703,"headline":"Incyte: Profitable Biotech That Could Be Close To Exploding"}, {"id":140937696,"url":"https://finnhub.io/api/news?id=a553b39a41af82b706247ec18aa19d8ef3e0571d48245853b03dd7a9bbf8d0b5","image":"","source":"Benzinga","related":"INCY","summary":"Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a","category":"company","datetime":1784293970,"headline":"Incyte To Present New Phase 1 Solid Tumor Data, Including KRAS G12D and TGFβR2×PD‑1 Programs, At ESMO 2026"}, {"id":140925108,"url":"https://finnhub.io/api/news?id=05939657d6c850e1eebf82da32b184016550b8b3393b7ffd86aea3de083daf7d","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1285391908/image_1285391908.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"INCY","summary":"Steven Cress, Seeking Alpha's Head of Quant, provides his top 2 stocks for H2 2026.","category":"company","datetime":1784220120,"headline":"Steven Cress' Top 2 Stocks H2 2026"}, {"id":140919919,"url":"https://finnhub.io/api/news?id=ac38e40815783f8ec5171d72b4c86aa0d5496672e10888f4bb0f5347b866864d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.","category":"company","datetime":1784207177,"headline":"Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside"}, {"id":140917605,"url":"https://finnhub.io/api/news?id=9b0419b4f5188dcfa8be73ee7427bd5e72acdec1e9a88099cd671cf7f6b7d196","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Incyte is scheduled to release its second-quarter results later this month, with analysts projecting a double-digit increase in its bottom line figure.","category":"company","datetime":1784164726,"headline":"What to Expect From Incyte's Q2 2026 Earnings Report"}, {"id":140911616,"url":"https://finnhub.io/api/news?id=a21356dd71ba4a29f749ef6a9402b694ac4b5f7bec9fd511f75b6d42947c718e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Incyte has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 8.6% to $114.25 per share while the index has gained 8.2%.","category":"company","datetime":1784133437,"headline":"Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings?"}, {"id":140902248,"url":"https://finnhub.io/api/news?id=40bf04d5730d9953faaebb0f7710b06678dc230e6d9574421efc3f181641f562","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2250479883/image_2250479883.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"INCY","summary":"Syndax Pharma outlook: Revuforj first-mover edge, pipeline catalysts (Niktimvo), and profitability path amid misses. Click here to read more about SNDX.","category":"company","datetime":1784047680,"headline":"A Fresh Look At Syndax Pharmaceuticals"}, {"id":140898821,"url":"https://finnhub.io/api/news?id=915e96bee8a935b573658cd266498a4469639874ea9e63198fef5e4fae5c3427","image":"","source":"Benzinga","related":"INCY","summary":"Barclays analyst Etzer Darout maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $117 to $134.","category":"company","datetime":1784012695,"headline":"Barclays Maintains Overweight on Incyte, Raises Price Target to $134"}, {"id":140890161,"url":"https://finnhub.io/api/news?id=e25110c78ca2177615e41497f4272b141937d60a5e1b269003abf9d7270f7d7c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.2% and","category":"company","datetime":1783971281,"headline":"Sector Update: Healthcare Stocks Advance Late Afternoon"}, {"id":140888428,"url":"https://finnhub.io/api/news?id=ed15eb87356bea39d17c294679a13f32dbb5cc7c416f7aa1579ca7722654403b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.","category":"company","datetime":1783964231,"headline":"Own Regeneron For Biotech Growth? Incyte Is Making Its Case."}, {"id":140888631,"url":"https://finnhub.io/api/news?id=f141f5f93afa2376a17eccdb81a87ce04b3a142187092e639c75235d6edf9843","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Incyte (INCY) is back in focus after releasing complete safety and efficacy data from a Phase 1/2 study of latarcibart, its investigational monoclonal antibody for von Willebrand disease, and advancing the program into Phase 3. See our latest analysis for Incyte. Against this backdrop, Incyte’s shares have been firming, with a 30 day share price return of 7.54% and a 90 day share price return of 19.47%, while the 1 year total shareholder return of 66.78% points to strong longer term momentum...","category":"company","datetime":1783962522,"headline":"Incyte (INCY) Could Be 8% Overvalued As Latarcibart Moves Into Phase 3"}, {"id":140887161,"url":"https://finnhub.io/api/news?id=aed32e5440335247d1d54e1a848e0f60f7f66ffd9371a9b6a69f6d8f58de61e3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Incyte recently reported full Phase 1/2 multidose data for latarcibart (VGA039), an investigational, once‑monthly subcutaneous monoclonal antibody that targets Protein S and showed substantial reductions in bleeding rates across all von Willebrand disease types, with a favorable safety profile, in 16 treated patients. The therapy’s potential to offer the first self‑administered, once‑monthly prophylactic option for VWD, versus frequent intravenous factor infusions, could materially change...","category":"company","datetime":1783955436,"headline":"How Investors May Respond To Incyte (INCY) Latarcibart Data In Von Willebrand Disease Prophylaxis"}, {"id":140887162,"url":"https://finnhub.io/api/news?id=a54ac809d7cdb682cc8a30ea6b1cc5e4ce52c4dcab3da92267c40898fb12ac33","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Incyte Corporation (NASDAQ:INCY) on Monday reported complete Phase 1/2 multidose data for latarcibart (VGA039), showing substantial reductions in bleeding episodes and a favorable safety profile in patients with von Willebrand disease (VWD). VWD is the most common inherited bleeding disorder, affecting about 1% of the population. It is caused by a deficiency or malfunction of the von Willebrand factor, a blood protein needed for platelets to clot properly. Read Also: Incyte Bets $1.25 Billion On","category":"company","datetime":1783949108,"headline":"Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder"}, {"id":140886052,"url":"https://finnhub.io/api/news?id=a487fe79641a5675cdde5b8921f6b47577015aee11c289601fe16b2ede882a21","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks fared in Q1, starting with Incyte (NASDAQ:INCY).","category":"company","datetime":1783945839,"headline":"Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks"}, {"id":140887931,"url":"https://finnhub.io/api/news?id=e7bc2ada588cf2adac84f1c0501fa0221bd7ce5aaec251bb11ce57714a088ce5","image":"https://image.cnbcfm.com/api/v1/image/108331043-1783365848624-gettyimages-2280068333-sc1_1154_pvccmh9y.jpeg?v=1783365884&w=1920&h=1080","source":"CNBC","related":"INCY","summary":"Economy is one of the most important categories in CNBC’s annual America’s Top States for Business rankings. Several states stand out for economic strength.","category":"company","datetime":1783936801,"headline":"The 10 best state economies in America in 2026"}, {"id":140887877,"url":"https://finnhub.io/api/news?id=cdbb5549ed0b6511090695ecb351e10424f0d4e6f46e9305e90cc729adbbc3b3","image":"","source":"Benzinga","related":"INCY","summary":"BMO Capital analyst Evan Seigerman maintains Incyte (NASDAQ:INCY) with a Market Perform and raises the price target from $94 to $112.","category":"company","datetime":1783933048,"headline":"BMO Capital Maintains Market Perform on Incyte, Raises Price Target to $112"}, {"id":140883892,"url":"https://finnhub.io/api/news?id=e514bb5e9f92d121de0f4c7a453af020ffe4125b9dd18482ef5eed90ce7c69d7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"WILMINGTON, Del., July 13, 2026--Phase 1/2 Multidose Data for VGA039 (Latarcibart) Show Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types","category":"company","datetime":1783929600,"headline":"Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types"}, {"id":140856160,"url":"https://finnhub.io/api/news?id=f876d79aaa0f42fdd94092d76f6a95c9aa9d7384368c9d05ba671d9e973b0e50","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195840496/image_2195840496.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"INCY","summary":"Seeking Alpha's Head of Quant, Steve Cress, provides a mid-year update on his top 10 stocks for 2026.","category":"company","datetime":1783622040,"headline":"Steven Cress' Top 10 Stocks For 2026 (Mid-Year Review)"}, {"id":140846990,"url":"https://finnhub.io/api/news?id=69f5b1271559deaac456457fd86796529813269ee230961a08b70f458add660c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.","category":"company","datetime":1783556700,"headline":"2 Fast-Growing Pharmaceutical Stocks to Buy Now"}, {"id":140843654,"url":"https://finnhub.io/api/news?id=9d1002029bc82808b25ccb335642eb3cc1cc4ba8647e4508fc48b73a0d083390","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1314804423/image_1314804423.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"INCY","summary":"Jonathan Faison, who runs ROTY biotech community, shares why much of the current euphoria in biotech is driven by fundamentals.","category":"company","datetime":1783519200,"headline":"Biotech Euphoria Driven By Fundamentals"}, {"id":140840573,"url":"https://finnhub.io/api/news?id=5e139a297017ff79fead3a17df77dd2984859059085fd34751ce71e2a30a986a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.","category":"company","datetime":1783514909,"headline":"Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside"}, {"id":140840730,"url":"https://finnhub.io/api/news?id=fb64b0659f3223fcb2bf9e7a59579554e2b2943853a21329479369a2c1004907","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"INCY","summary":"WILMINGTON, Del., July 08, 2026--Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026.","category":"company","datetime":1783512000,"headline":"Incyte to Report Second Quarter Financial Results"}, {"id":140834756,"url":"https://finnhub.io/api/news?id=dc3cf7f4fad94fb261d230d6d8782221966701b25c4009d4f60cd68acc524703","image":"","source":"Benzinga","related":"INCY","summary":"RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $95 to $99.","category":"company","datetime":1783424452,"headline":"RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $99"}
data_source finnhub_news_keyword_model
article_count 8
negative_hits 0
positive_hits 4
recomputed_at_score true
sentiment_score_raw 1.2
source_article_count 84
discarded_article_count 61
sentimentPoints 6

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 5 5/110 100% 5
資金流 8.4 20/110 42% 8.4
市場環境 6.6 15/110 44% 6.6
催化劑 2 20/110 10% 2
風險管理 5.9 10/110 59% 5.9
技術信號 17.8 30/110 59.33% 17.8
情緒分析 6 10/110 60% 6

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 8/50
ret_5d -0.0375
max_score 50
max_total 50
raw_total 8
vcp_bonus 0
vol_ratio 1.2393
ret_points 0
vol_points 4
range_ratio 1.0504
volat_points 0
day_range_pct 0.0357
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 4
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Elevated
reason risk management score >= 5/10

position

score 1.3

details

atrPct 3.8762
turnoverUsdM 282.9653
liquidityPoints 0.6
volatilityPoints 0.7
rrPoints 1.4

stopLevels

symbol US.INCY
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 109.2028

strength_details

ma_score 1.5
atr_score 1
rsi_score 2
macd_score 1.5
volume_score 2
market_adjustment 1
risk_reward_ratio 1
stop_loss_percent 7.8
take_profit_price 127.8249
target_multiplier 1.9
technical_strength 1.63
take_profit_percent 8
positionPoints 1.3
stopLossPoints 1.2

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 7.7523
diversificationPoints 2

Calculation audit log

基本面分析總分: 5/5分
資金流分析總分: 8.4/20分
市場環境分析總分: 6.6/15分
催化劑分析: 2/20分
風險管理總分: 5.9/10分
技術信號分析總分: 17.8/30分
情緒分析: 6/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 85.71
atr
atr 4.5886
rule ATR / current price; lower volatility scores higher
score 4
atr_pct 3.88
cci
rule Cursor_18.24 CCI bands
level 弱勢
score 4
value -14.67
cmf
rule Cursor_18.24 CMF bands
level 派發
score 2
value -0.011
kdj
d 39.14
j 2.98
k 27.09
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 入貨中
score 8
value 62.45
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 4
trend 弱勢
value 7990687
recentSlope -224511.3
previousSlope 679600
rsi
value 51.62
sar
rule Cursor_18.24 Parabolic SAR
score 4
trend 下降
value 130.0286
position SAR喺價上
distancePct 9.84
previousTrend 下降
ma50
value 110.9026
macd
macd 2.5295
trend 中性偏多
signal 3.1987
histogram -0.6692
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 2
value 120.1706
position <VWAP
consecutiveAbove 0
volume
rule Cursor_18.24 volume ratio
level 有量
ratio 1.21
score 6
avgVolume 1980641
currentVolume 2390313
derived
ma20 118.681
ma50 110.9026
prevClose 119.8
avgVolume10 2490681
avgVolume20 1980641
changePercent -1.19
avgVolumeForScore 1980641
ma_cross
ma20 118.681
ma50 110.9026
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 118.688
prevMa50 110.477
spreadPct 7.01
isVolumeBreakout false
bollinger
lower 110.8935
upper 126.4685
position 中間
rsi_short
value 16.62
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 1.21

Raw calculation JSON

 
{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.3,
      "details": {
        "atrPct": 3.8761615137692176,
        "turnoverUsdM": 282.96525293999997,
        "liquidityPoints": 0.6,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.INCY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 109.2028,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 2,
        "macd_score": 1.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 7.8,
      "take_profit_price": 127.8249,
      "target_multiplier": 1.9,
      "technical_strength": 1.63,
      "take_profit_percent": 8
    },
    "positionPoints": 1.3,
    "stopLossPoints": 1.2,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 7.752323027538435,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 59.7,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 51.7,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 8
  },
  "market": {
    "ma20": 118.681,
    "ma50": 110.9026,
    "close": 118.38,
    "prevClose": 119.8,
    "avgVolume20": 1980641,
    "volumeRatio": 1.21,
    "changePercent": -1.19
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 8,
    "details": {
      "ret_5d": -0.037482722172534344,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 8,
      "vcp_bonus": 0,
      "vol_ratio": 1.2392714660113386,
      "ret_points": 0,
      "vol_points": 4,
      "range_ratio": 1.050355040810507,
      "volat_points": 0,
      "day_range_pct": 0.03573238722757226,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 4,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 59.7,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 100,
        "contribution": 5
      },
      {
        "raw": 8.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 42,
        "contribution": 8.4
      },
      {
        "raw": 6.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 44,
        "contribution": 6.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 5.9,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 59,
        "contribution": 5.9
      },
      {
        "raw": 17.8,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 59.33,
        "contribution": 17.8
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 51.7,
    "details": [
      "基本面分析總分: 5/5分",
      "資金流分析總分: 8.4/20分",
      "市場環境分析總分: 6.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 5.9/10分",
      "技術信號分析總分: 17.8/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 5,
      "資金流": 8.4,
      "市場環境": 6.6,
      "情緒分析": 6,
      "技術信號": 17.8,
      "風險管理": 5.9
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.5,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.75,
          "turnoverUsdM": 282.96525293999997,
          "volumePoints": 0.5,
          "revenuePoints": 0.75,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 3.2,
          "obvPoints": 1.6,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.INCY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 3,
            "details": {
              "qqq": {
                "ma20": 700.4619942500001,
                "ma50": 714.69519954,
                "name": "QQQ",
                "close": 714.62,
                "points": 1
              },
              "spy": {
                "ma20": 749.25550215,
                "ma50": 746.7324035600001,
                "name": "SPY",
                "close": 768.53003,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.8761615137692176,
          "atrPoints": 2,
          "cciPoints": 1.6,
          "vixPoints": 0,
          "marketTrendPoints": 3
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141124378,
                "url": "https://finnhub.io/api/news?id=2e9cdc845599ec8de38ca915bc2ee2ada5fb327446645dc572f0ce9a833e59b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "REGN vs. INCY: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1785944402,
                "headline": "REGN or INCY: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 141089558,
                "url": "https://finnhub.io/api/news?id=d193e1a9da786dba927302825e1ac4e436b47d2a4ef395a053f2eb026d40287d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) is back in focus after the European Commission approved Opzelura cream for moderate atopic dermatitis in certain adults, shortly after the company reported second quarter results and raised full year sales guidance. See our latest analysis for Incyte. The recent European approval for Opzelura and the stronger second quarter results come after a period of firm momentum in Incyte’s stock, with a 90 day share price return of 23.33% and a 1 year total shareholder return of...",
                "category": "company",
                "datetime": 1785618581,
                "headline": "Incyte (INCY) Won EU Approval For Opzelura, Has The Market Already Priced It In?"
              },
              {
                "id": 141089559,
                "url": "https://finnhub.io/api/news?id=66ee3d96f932a33253226f3002e3e870617e598368af7691a991672344718603",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte stock has delivered a strong run over the last three years, yet the broader valuation checks suggest it may no longer stand out as a clear bargain at current levels. Incyte has returned 87.8% over the past three years, which puts fresh focus on whether recent gains already reflect much of the good news. Recent approvals for Opzelura in atopic dermatitis and new partnership activity can support confidence in future revenue, while execution risk around expanding treatments and...",
                "category": "company",
                "datetime": 1785614991,
                "headline": "Incyte (INCY) Stock Trades Reasonable On Earnings While Returns Look Strong"
              },
              {
                "id": 141089087,
                "url": "https://finnhub.io/api/news?id=4cafa0c0c576492af58b5a037d3e4d674d60091cc75d218a9fff9032cba9f660",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "In July 2026, Incyte received European Commission approval for Opzelura (ruxolitinib) cream to treat moderate atopic dermatitis in adults who do not respond adequately to, or cannot use, topical corticosteroids and calcineurin inhibitors, supported by positive Phase 3 data showing improved symptoms, quality of life and tolerability. This second European indication for Opzelura, alongside strong Phase 3b TRuE-AD4 outcomes, highlights Incyte’s growing dermatology franchise and its ability to...",
                "category": "company",
                "datetime": 1785611472,
                "headline": "European Opzelura Approval in Atopic Dermatitis Could Be A Game Changer For Incyte (INCY)"
              },
              {
                "id": 141088479,
                "url": "https://finnhub.io/api/news?id=817f6fcd57e34aec0ab49f7cd5b44a5e25bd5579e73d8284a3f8cfe53577ab60",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "European Commission approves Opzelura (ruxolitinib) cream as the first steroid free topical JAK inhibitor for adults with moderate atopic dermatitis in the EU. Decision is based on Phase 3b TRuE AD4 data in adult patients with mild to moderate atopic dermatitis. Approval expands Opzelura's use in Europe and adds a new dermatology revenue opportunity for Incyte. For investors following Incyte, ticker NasdaqGS:INCY, this EU approval adds a fresh piece of news around its dermatology efforts...",
                "category": "company",
                "datetime": 1785604078,
                "headline": "Incyte (INCY) Wins EU Approval For Opzelura In Adult Moderate Atopic Dermatitis"
              },
              {
                "id": 141046508,
                "url": "https://finnhub.io/api/news?id=6f63228fc5636768c7177d6706a78488fb4357da7446b67f6d5006217d3645c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte Corp (INCY) reports a 38% increase in total revenue, raises full-year guidance, and highlights significant advancements in its diverse product pipeline.",
                "category": "company",
                "datetime": 1785265310,
                "headline": "Incyte Corp (INCY) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and Strategic ..."
              },
              {
                "id": 141045188,
                "url": "https://finnhub.io/api/news?id=9b51439141c29da15f6773f0c3e11b7989e81beaf05eadbc1aee88f09c1c18eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.",
                "category": "company",
                "datetime": 1785256800,
                "headline": "INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised"
              },
              {
                "id": 141044114,
                "url": "https://finnhub.io/api/news?id=12a76a839b9588cb7b135e7669983aa7815af3ca9ca2dbfe5fcfa664b6ef1426",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
                "category": "company",
                "datetime": 1785245406,
                "headline": "Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics"
              }
            ],
            "raw_source": [
              {
                "id": 141137504,
                "url": "https://finnhub.io/api/news?id=5ba2cc11a9ecb49edc66612183fe45868379495b15bc40aff39523368206fff5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.",
                "category": "company",
                "datetime": 1786029660,
                "headline": "Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised"
              },
              {
                "id": 141124378,
                "url": "https://finnhub.io/api/news?id=2e9cdc845599ec8de38ca915bc2ee2ada5fb327446645dc572f0ce9a833e59b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "REGN vs. INCY: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1785944402,
                "headline": "REGN or INCY: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 141125130,
                "url": "https://finnhub.io/api/news?id=ec67b5cb9214019a7c398a6f91533f609baf347be1299b6c7d6517db16aaed99",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Mizuho  analyst Salim Syed   maintains Incyte (NASDAQ:INCY) with a Outperform and raises the price target from $121 to $137.",
                "category": "company",
                "datetime": 1785852726,
                "headline": "Mizuho Maintains Outperform on Incyte, Raises Price Target to $137"
              },
              {
                "id": 141099326,
                "url": "https://finnhub.io/api/news?id=cc2662e857815e4ce5bff63b03718501328f075fffcc39c614651be14387b757",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2156417320/image_2156417320.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "AbbVie Inc. stock fell 6.2% after a 52-week high despite strong Q2 earnings; Rinvoq and Elahere sales surged. Click for this ABBV earnings udpate.",
                "category": "company",
                "datetime": 1785751531,
                "headline": "AbbVie: Strong Q2 And New Catalysts Keep Me Bullish"
              },
              {
                "id": 141099586,
                "url": "https://finnhub.io/api/news?id=2236694b532821ccd17ec78e8aa739f376a9517d1f738f8e47c88a2f4f048e45",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/03/Warsaw--Poland--31-July-2024--Wola-Busin.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Top Wall Street analysts changed their outlook on top names. Barclays raised DAR&#39;s target to $65, BTIG boosted SNOW&#39;s target to $340, and JP Morgan upgraded LYB to Overweight.",
                "category": "company",
                "datetime": 1785744979,
                "headline": "Snowflake To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday"
              },
              {
                "id": 141103928,
                "url": "https://finnhub.io/api/news?id=c2efedbdc50b89967269d5ad051b03083f0c004678077351407ad8b011b50cca",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Leerink Partners  analyst Andrew Berens   maintains Incyte (NASDAQ:INCY) with a Outperform and raises the price target from $131 to $155.",
                "category": "company",
                "datetime": 1785739354,
                "headline": "Leerink Partners Maintains Outperform on Incyte, Raises Price Target to $155"
              },
              {
                "id": 141103929,
                "url": "https://finnhub.io/api/news?id=8fc96a3937efe7f6ca663d5460777c2b0f06f5cab3afbd580c097b489b24e7a3",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "HC Wainwright &amp; Co.  analyst Mitchell S. Kapoor   reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $150 price target.",
                "category": "company",
                "datetime": 1785737925,
                "headline": "HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target"
              },
              {
                "id": 141103930,
                "url": "https://finnhub.io/api/news?id=485fe4314e98cd1700421551c15cbb80275c7ebc3755e5fdc7bff0b5ada4863f",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "MinjuvI (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen listed on the Pharmaceutical Benefits Scheme",
                "category": "company",
                "datetime": 1785724582,
                "headline": "Reported Sunday, Incyte's Minjuvi Plus Rituximab And Lenalidomide Now PBS-Funded In Australia, First New R/R Follicular Lymphoma Therapy Reimbursed In Nine Years"
              },
              {
                "id": 141089558,
                "url": "https://finnhub.io/api/news?id=d193e1a9da786dba927302825e1ac4e436b47d2a4ef395a053f2eb026d40287d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) is back in focus after the European Commission approved Opzelura cream for moderate atopic dermatitis in certain adults, shortly after the company reported second quarter results and raised full year sales guidance. See our latest analysis for Incyte. The recent European approval for Opzelura and the stronger second quarter results come after a period of firm momentum in Incyte’s stock, with a 90 day share price return of 23.33% and a 1 year total shareholder return of...",
                "category": "company",
                "datetime": 1785618581,
                "headline": "Incyte (INCY) Won EU Approval For Opzelura, Has The Market Already Priced It In?"
              },
              {
                "id": 141089559,
                "url": "https://finnhub.io/api/news?id=66ee3d96f932a33253226f3002e3e870617e598368af7691a991672344718603",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte stock has delivered a strong run over the last three years, yet the broader valuation checks suggest it may no longer stand out as a clear bargain at current levels. Incyte has returned 87.8% over the past three years, which puts fresh focus on whether recent gains already reflect much of the good news. Recent approvals for Opzelura in atopic dermatitis and new partnership activity can support confidence in future revenue, while execution risk around expanding treatments and...",
                "category": "company",
                "datetime": 1785614991,
                "headline": "Incyte (INCY) Stock Trades Reasonable On Earnings While Returns Look Strong"
              },
              {
                "id": 141089087,
                "url": "https://finnhub.io/api/news?id=4cafa0c0c576492af58b5a037d3e4d674d60091cc75d218a9fff9032cba9f660",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "In July 2026, Incyte received European Commission approval for Opzelura (ruxolitinib) cream to treat moderate atopic dermatitis in adults who do not respond adequately to, or cannot use, topical corticosteroids and calcineurin inhibitors, supported by positive Phase 3 data showing improved symptoms, quality of life and tolerability. This second European indication for Opzelura, alongside strong Phase 3b TRuE-AD4 outcomes, highlights Incyte’s growing dermatology franchise and its ability to...",
                "category": "company",
                "datetime": 1785611472,
                "headline": "European Opzelura Approval in Atopic Dermatitis Could Be A Game Changer For Incyte (INCY)"
              },
              {
                "id": 141088479,
                "url": "https://finnhub.io/api/news?id=817f6fcd57e34aec0ab49f7cd5b44a5e25bd5579e73d8284a3f8cfe53577ab60",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "European Commission approves Opzelura (ruxolitinib) cream as the first steroid free topical JAK inhibitor for adults with moderate atopic dermatitis in the EU. Decision is based on Phase 3b TRuE AD4 data in adult patients with mild to moderate atopic dermatitis. Approval expands Opzelura's use in Europe and adds a new dermatology revenue opportunity for Incyte. For investors following Incyte, ticker NasdaqGS:INCY, this EU approval adds a fresh piece of news around its dermatology efforts...",
                "category": "company",
                "datetime": 1785604078,
                "headline": "Incyte (INCY) Wins EU Approval For Opzelura In Adult Moderate Atopic Dermatitis"
              },
              {
                "id": 141086380,
                "url": "https://finnhub.io/api/news?id=a1b1742c992e86e8d9ed9e79579e23316e166304fcfe86f582799192885bc109",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.",
                "category": "company",
                "datetime": 1785571917,
                "headline": "1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds"
              },
              {
                "id": 141056000,
                "url": "https://finnhub.io/api/news?id=25bcacd240f3bfeeac2755d895eda5e1df2a34a1738e86b8bb28e50d7b71921a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The European Commission on Wednesday approved Incyte’s Opzelura cream as the first steroid-free topical treatment of its kind for adults with moderate eczema who do not get enough relief from standard creams.",
                "category": "company",
                "datetime": 1785345731,
                "headline": "Incyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod"
              },
              {
                "id": 141057549,
                "url": "https://finnhub.io/api/news?id=74e2a18e2341a38b90ab247eb729d4ca76f6125ef10ac31a2524925b0e83eec3",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $99 to $109.",
                "category": "company",
                "datetime": 1785332115,
                "headline": "RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $109"
              },
              {
                "id": 141057550,
                "url": "https://finnhub.io/api/news?id=40386d9cb4aac281a6b0481ca34deb27152a95af696e43543d3343140b79a456",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/29/Konskie--Poland---December-08--2024-Incy.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Incyte Corp. (INCY) reported strong Q2 results, raised full-year sales guidance. CEO cites sales growth, pipeline progress, and business development. Analysts maintain buy ratings with price target increases.",
                "category": "company",
                "datetime": 1785322406,
                "headline": "Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results"
              },
              {
                "id": 141057551,
                "url": "https://finnhub.io/api/news?id=bc5ca8c81baad7c9f72efd5d2ea26272d756b81ce616c2718a93d4e8af4c07bc",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Guggenheim   maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $136 to $150.",
                "category": "company",
                "datetime": 1785320483,
                "headline": "Guggenheim Maintains Buy on Incyte, Raises Price Target to $150"
              },
              {
                "id": 141052276,
                "url": "https://finnhub.io/api/news?id=1a077f383181680361593f4fc0cdfe88a9cc78b10e55fc46662e3e357a704820",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "WILMINGTON, Del., July 29, 2026--Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the EU for Adults with Moderate Atopic Dermatitis",
                "category": "company",
                "datetime": 1785319200,
                "headline": "Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis"
              },
              {
                "id": 141057552,
                "url": "https://finnhub.io/api/news?id=5c418c9628fe19002024d6653630d9b9fee4635bde2599fcce60253b83268ed3",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "BMO Capital  analyst Evan Seigerman   maintains Incyte (NASDAQ:INCY) with a Market Perform and raises the price target from $112 to $130.",
                "category": "company",
                "datetime": 1785318946,
                "headline": "BMO Capital Maintains Market Perform on Incyte, Raises Price Target to $130"
              },
              {
                "id": 141053819,
                "url": "https://finnhub.io/api/news?id=d2c922f03b1f56364c6cb0efc7927b30fcba8881b67cae6e586801e9d792f6b8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/29/Healthcare-stocks.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "RSI warning: 3 overbought health care stocks could be flashing a real warning to investors with high momentum trading preferences",
                "category": "company",
                "datetime": 1785314722,
                "headline": "Top 3 Health Care Stocks That May Implode This Month"
              },
              {
                "id": 141057554,
                "url": "https://finnhub.io/api/news?id=f173421e6fdb09349bc9b98244ae8f6da6a4f51f094f121839ef819f0bdc7f4a",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Barclays  analyst Etzer Darout   maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $134 to $139.",
                "category": "company",
                "datetime": 1785313264,
                "headline": "Barclays Maintains Overweight on Incyte, Raises Price Target to $139"
              },
              {
                "id": 141057555,
                "url": "https://finnhub.io/api/news?id=15490808f6c716b8670ec8e4a3ac083f03234778ad32f16a672785d1ef10aeb7",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "HC Wainwright &amp; Co.  analyst Mitchell S. Kapoor   maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $140 to $150.",
                "category": "company",
                "datetime": 1785306378,
                "headline": "HC Wainwright & Co. Maintains Buy on Incyte, Raises Price Target to $150"
              },
              {
                "id": 141057556,
                "url": "https://finnhub.io/api/news?id=dd8bfd44f7f4c71f85276aabd63a2477ae821d094b6f0e3d8cd4a88bf11d6197",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "The European Commission approval is based on Phase 3b TRuE‑AD4 data which demonstrated that Opzelura® (ruxolitinib) cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment",
                "category": "company",
                "datetime": 1785304963,
                "headline": "Incyte Says EC Approves Opzelura Cream For Treatment Of Moderate Atopic Dermatitis In Adult Patients"
              },
              {
                "id": 141046067,
                "url": "https://finnhub.io/api/news?id=28852786028f830f8c93415f5e5497f7948584b12d1d51d853db9c580c37e955",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.",
                "category": "company",
                "datetime": 1785265501,
                "headline": "Exploring the top movers within the S&P500 index during today's session."
              },
              {
                "id": 141046508,
                "url": "https://finnhub.io/api/news?id=6f63228fc5636768c7177d6706a78488fb4357da7446b67f6d5006217d3645c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte Corp (INCY) reports a 38% increase in total revenue, raises full-year guidance, and highlights significant advancements in its diverse product pipeline.",
                "category": "company",
                "datetime": 1785265310,
                "headline": "Incyte Corp (INCY) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and Strategic ..."
              },
              {
                "id": 141044671,
                "url": "https://finnhub.io/api/news?id=60d82d912a0cbbf84300ba4e349dd2be3cc82511f788156598ee6f9cfa8ab719",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below.",
                "category": "company",
                "datetime": 1785258300,
                "headline": "Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below."
              },
              {
                "id": 141045188,
                "url": "https://finnhub.io/api/news?id=9b51439141c29da15f6773f0c3e11b7989e81beaf05eadbc1aee88f09c1c18eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.",
                "category": "company",
                "datetime": 1785256800,
                "headline": "INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised"
              },
              {
                "id": 141048636,
                "url": "https://finnhub.io/api/news?id=108957862ddf2373a16785e6688d3ad7e0cb2a9cd5b6003f083b48a5bf45f5e1",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/28/Konskie--Poland---December-08--2024-Incy.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Incyte (INCY) Q2 earnings beat estimates with $1.67B revenue, $3.09 EPS. Full-year sales guidance raised. Shares rally to new 52-week high.",
                "category": "company",
                "datetime": 1785251422,
                "headline": "Incyte Says It's No Longer A One-Drug Story"
              },
              {
                "id": 141045820,
                "url": "https://finnhub.io/api/news?id=6a737a4ae55d24ee85b70d55e05108fe48c0483ee293c4c3449d86ca61ec7390",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "2026-07-28. The following slide deck was published by Incyte Corporation in conjunction with their 2026 Q2 earnings call.",
                "category": "company",
                "datetime": 1785249140,
                "headline": "Incyte Corporation 2026 Q2 - Results - Earnings Call Presentation"
              },
              {
                "id": 141044113,
                "url": "https://finnhub.io/api/news?id=525ea22bfc0aacfce1da10e0d3444dc997e7bc6a9a938e2bf465d99100229ba9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (NASDAQ:INCY) reported second-quarter 2026 net product sales of $1.49 billion, up 40% from a year earlier, supported by demand growth across its marketed portfolio and a one-time non-cash benefit tied to the resolution of a CMS matter involving OPZELURA. Excluding the $246 million one-time b",
                "category": "company",
                "datetime": 1785247454,
                "headline": "Incyte Q2 Earnings Call Highlights"
              },
              {
                "id": 141044114,
                "url": "https://finnhub.io/api/news?id=12a76a839b9588cb7b135e7669983aa7815af3ca9ca2dbfe5fcfa664b6ef1426",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
                "category": "company",
                "datetime": 1785245406,
                "headline": "Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics"
              },
              {
                "id": 141042794,
                "url": "https://finnhub.io/api/news?id=fbd9cd328e5d6e2a42fcc9224756b806eabc2ce57cecc5da3f7d9c4db3a3e37e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (NASDAQ:INCY) reported better-than-expected second-quarter earnings and revenue on Tuesday, although its shares edged lower in pre-market trading after the company issued full-year sales guidance that came in below analysts’ expectations. The biotechnology group delivered strong growth across its commercial portfolio, supported by higher sales from several key products and continued pipeline progress.",
                "category": "company",
                "datetime": 1785245376,
                "headline": "Incyte Tops Second-Quarter Expectations but Shares Slip on Lower Revenue Outlook"
              },
              {
                "id": 141042029,
                "url": "https://finnhub.io/api/news?id=c96d09c019061ce7d6feed85e21a0c0f1efc7c1b939fc4a7215f66194fd03c5a",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_16_065e226ebd.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "Incyte beat Q2 estimates but slashed full-year guidance and raised expenses on a $1.27B acquisition, sending shares down 31% pre-market.",
                "category": "company",
                "datetime": 1785241400,
                "headline": "Incyte (NASDAQ:INCY): High Growth Stock Slides on Q2 Beat but Steep Guidance Cut"
              },
              {
                "id": 141044416,
                "url": "https://finnhub.io/api/news?id=0d4f33d7e5de25a063c9dd5083916e021be4ec9699b53a15cb53d71306169487",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte Corporation (INCY) Q2 2026 Earnings Call July 28, 2026 8:00 AM EDTCompany ParticipantsAlexis Smith - VP & Head of Investor RelationsWilliam Meury...",
                "category": "company",
                "datetime": 1785241392,
                "headline": "Incyte Corporation (INCY) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141042795,
                "url": "https://finnhub.io/api/news?id=3fcb7f376b8aeff1d961740a2084bb1f9106c89c8c86847feed2af8c200c0c8c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) delivered earnings and revenue surprises of +54.50% and +14.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785240902,
                "headline": "Incyte (INCY) Q2 Earnings and Revenues Top Estimates"
              },
              {
                "id": 141041896,
                "url": "https://finnhub.io/api/news?id=deb542f41aa7f434c46038cc10d4ee4c66e9da2a1fdb0bb664275f2f273c979d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 37.7% year on year to $1.67 billion. On the other hand, the company’s full-year revenue guidance of $5.20 billion at the midpoint came in 9.2% below analysts’ estimates. Its non-GAAP profit of $3.09 per share was 43.9% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785238648,
                "headline": "Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q2 CY2026 But Full-Year Sales Guidance Misses Expectations Significantly"
              },
              {
                "id": 141048637,
                "url": "https://finnhub.io/api/news?id=fca5e3f6a42f39cc70236eb123ad64a4acd4353b60877406ffeff2a86ed0df57",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "In a new SEC filing on July 27, it was unveiled that Heeson, EVP at Incyte (NASDAQ:INCY), acquired stock options for 15,423 shares.\nWhat Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on",
                "category": "company",
                "datetime": 1785236445,
                "headline": "A Noteworthy Decision By Lee Heeson As Acquires $130K In Incyte Stock Options"
              },
              {
                "id": 141048638,
                "url": "https://finnhub.io/api/news?id=021975f7161fbfbaa830a159bef61b90420ef6b1ff29263b4995686d0d8bec97",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "James Michael Morrissey, EVP at Incyte (NASDAQ:INCY), reported acquisition of company stock options on July 27, according to a new SEC filing.\nWhat Happened: Uncovered in a Form 4 filing on Monday with the U.S.",
                "category": "company",
                "datetime": 1785236444,
                "headline": "James Michael Morrissey Expands Holdings With $54K Incyte Stock Options Acquisition"
              },
              {
                "id": 141041897,
                "url": "https://finnhub.io/api/news?id=32ab29909cba625ffb15085d0d5c96aeb1a13aba9148a5a5c07b9ef9e1684be5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "WILMINGTON, Del., July 28, 2026--Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates",
                "category": "company",
                "datetime": 1785236400,
                "headline": "Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates"
              },
              {
                "id": 141042267,
                "url": "https://finnhub.io/api/news?id=8eb48457e30ed759574902fad91ecc34d75054fa92fff08f027b6ddf02e62c26",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1329696857/image_1329696857.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte Corporation stock hits a 52-week high on latarcibart and strong Opzelura/Zynyz sales, but valuation & Iclusig demand drive a Hold. Click for an INCY update.",
                "category": "company",
                "datetime": 1785231217,
                "headline": "Incyte: From Buy To Hold After A 93% Rally (Rating Downgrade)"
              },
              {
                "id": 141045517,
                "url": "https://finnhub.io/api/news?id=0e144d572c44e6dd35db0b4ad9192f81b8967aff5437052626aaa80b900565f9",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/28/Servicenow-Office-Building-At-Their-Head.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "ServiceNow shares rose 6.9% to settle at $105.56 during the session, while Meta shares fell 0.2% to close at $593.87 on Monday.",
                "category": "company",
                "datetime": 1785226718,
                "headline": "ServiceNow, Meta, eBay And A Health Care Stock On CNBC’s ‘Final Trades’"
              },
              {
                "id": 141048640,
                "url": "https://finnhub.io/api/news?id=49a358e634e174f6a43f4be58a48b5abcc7cd8bc78e77527abf5ce0adf1233f0",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Incyte (NASDAQ:INCY) reported quarterly earnings of $3.09 per share which beat the analyst consensus estimate of $2.12 by 45.75 percent. This is a 96.82 percent increase over earnings of $1.57 per share from the same",
                "category": "company",
                "datetime": 1785222171,
                "headline": "Incyte Q2 Adj. EPS $3.09 Beats $2.12 Estimate, Sales $1.663B Beat $1.460B Estimate"
              },
              {
                "id": 141048641,
                "url": "https://finnhub.io/api/news?id=2464e6d7fb6f48df07bacaf57abaf7b834d6343bdac34e55985cb7be19debe3b",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Incyte (NASDAQ:INCY) raises FY2026 sales outlook from $4.770 billion-$4.940 billion to $5.130 billion-$5.260 billion vs $5.712 billion estimate.",
                "category": "company",
                "datetime": 1785222058,
                "headline": "Incyte Raises FY2026 Sales Guidance from $4.770B-$4.940B to $5.130B-$5.260B vs $5.712B Est"
              },
              {
                "id": 141031220,
                "url": "https://finnhub.io/api/news?id=2d9b5d3986d187fb5197c5ef9b0edab80e70e9a9efcc6abde9508b72f0a279da",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "INCY stock shows a perfect technical breakout setup with a 10/10 Technical Rating and 9/10 Setup Quality, featuring a bull flag pattern and strong momentum.",
                "category": "company",
                "datetime": 1785140441,
                "headline": "INCYTE CORP (NASDAQ:INCY) Exhibits Perfect Technical Breakout Setup with Strong Ratings"
              },
              {
                "id": 141030717,
                "url": "https://finnhub.io/api/news?id=ad4f54ff1118d2b454e581ed1dfde278d76cb2e6b8f5c0deb0f11f897d8b3228",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Tuesday before the bell. Here’s what to look for.",
                "category": "company",
                "datetime": 1785126542,
                "headline": "What To Expect From Incyte’s (INCY) Q2 Earnings"
              },
              {
                "id": 141021094,
                "url": "https://finnhub.io/api/news?id=3dc13cfc64224bb859f64f02def1e1e27d7a4e954ab5830cfdac7e3136c8c299",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (NasdaqGS:INCY) reported full safety and efficacy results from its Phase 1/2 study of latarcibart, a once monthly subcutaneous therapy for von Willebrand disease. The company announced the acquisition of VGA039 (latarcibart) through the purchase of Vega Therapeutics to support further development. Latarcibart carries breakthrough, fast track, orphan drug, and rare pediatric disease designations. For investors tracking Incyte, this update sits at the intersection of rare disease drug...",
                "category": "company",
                "datetime": 1785028292,
                "headline": "Incyte (INCY) Reports Full Latarcibart Data And Buys Vega Therapeutics"
              },
              {
                "id": 141007726,
                "url": "https://finnhub.io/api/news?id=05aeb953d4a880fc4fda1e7fcea9049fded33c60c04eb95d11f61b77c46633f7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "INCY heads into Q2 earnings with strong Jakafi demand, Opzelura momentum and rising royalties, fueling expectations for an earnings beat.",
                "category": "company",
                "datetime": 1784903880,
                "headline": "Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner?"
              },
              {
                "id": 141004058,
                "url": "https://finnhub.io/api/news?id=c6d0f91d2a89e21ca5c3f4abc044cb229a668a9fb38d1b68174b1f2d89a4b18a",
                "image": "https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "INCY stock shows strong earnings acceleration with 304% EPS growth and a perfect technical rating of 10, offering a defined breakout entry above $118.53 for momentum investors.",
                "category": "company",
                "datetime": 1784889636,
                "headline": "INCYTE CORP (NASDAQ:INCY) Screens as a High Growth Momentum Stock with a Breakout Setup"
              },
              {
                "id": 141008283,
                "url": "https://finnhub.io/api/news?id=a3c2f7a33f947eadc415691b2014909cd794a2fd6fde678f16f4a21b275753f3",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "JP Morgan  analyst Jessica Fye   maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $105 to $110.",
                "category": "company",
                "datetime": 1784817699,
                "headline": "JP Morgan Maintains Neutral on Incyte, Raises Price Target to $110"
              },
              {
                "id": 141008284,
                "url": "https://finnhub.io/api/news?id=4fa3db6dad4d32f41a2fe234aa35c45d9af1dc13c079b1d15b07f323c67cd202",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Morgan Stanley  analyst Judah Frommer   maintains Incyte (NASDAQ:INCY) with a Equal-Weight and raises the price target from $103 to $104.",
                "category": "company",
                "datetime": 1784815340,
                "headline": "Morgan Stanley Maintains Equal-Weight on Incyte, Raises Price Target to $104"
              },
              {
                "id": 140983371,
                "url": "https://finnhub.io/api/news?id=246cd6e33abf5deef3bb65b29fdbc58a7be46dfa9b5832fd032d7466d9b44940",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "LENZ Therapeutics, Inc. (LENZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1784728830,
                "headline": "Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline"
              },
              {
                "id": 140971589,
                "url": "https://finnhub.io/api/news?id=6e9cb60560ec50a9dc2a5e4ff31cabd7f9a7b79b6c11da15cec0d4eda37c4146",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, aiming to improve treatment convenience for patients.",
                "category": "company",
                "datetime": 1784644680,
                "headline": "HALO Inks Deal With INCY to Support Cancer Therapy Development"
              },
              {
                "id": 140972028,
                "url": "https://finnhub.io/api/news?id=ea7c64df2412008d93ad36aeb06ea3400274c5b1bce9ff23162a508765035b15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1784642419,
                "headline": "Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth"
              },
              {
                "id": 140972899,
                "url": "https://finnhub.io/api/news?id=b5039eeb51094b56bb15c6fbd0589d8bb8cc90e6bad42f0e7c7cf28242d94726",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160060870/image_1160060870.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Baker Brothers’ Q1 2026 13F: $17.42B biotech portfolio, top holdings & key buys/sells. Click here to read more.",
                "category": "company",
                "datetime": 1784640414,
                "headline": "Tracking Baker Brothers Portfolio: Q1 2026 Update"
              },
              {
                "id": 140977013,
                "url": "https://finnhub.io/api/news?id=0ca787b8d9130278ed0e7cc63691221b1f3d4ac2546209e8729a89acb3a868c6",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "HC Wainwright &amp; Co.  analyst Mitchell S. Kapoor   reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $140 price target.",
                "category": "company",
                "datetime": 1784615425,
                "headline": "HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $140 Price Target"
              },
              {
                "id": 140961075,
                "url": "https://finnhub.io/api/news?id=cffda6abacbacb10f1ab1cfb04b69376d4da6bdf87dd29f22082c36c286acd31",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Halozyme Therapeutics (NASDAQ:HALO) has entered into a global collaboration and license agreement with Incyte (NASDAQ:INCY) to support the development of subcutaneous formulations of INCA033989, expanding the use of its ENHANZE® drug delivery technology into another partnered program. Key Investor TakeawaysHalozyme signed a global collaboration and license agreement with Incyte centered on ENHANZE® drug delivery technology.",
                "category": "company",
                "datetime": 1784559763,
                "headline": "Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Development"
              },
              {
                "id": 140958865,
                "url": "https://finnhub.io/api/news?id=fe19aee917b682379e43eb92e51267d0b966c6a7e12e193fa0f4b1239dad3666",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Halozyme Therapeutics, Inc. (Nasdaq: HALO) (\"Halozyme\" or the \"Company\") today announced that it has entered into a global collaboration and license agreement with Incyte (Nasdaq: INCY) to evaluate additional subcutaneous formulations of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs), utilizing Halozyme's proprietary ENHANZE® drug delivery technology. The collaboration will focus on",
                "category": "company",
                "datetime": 1784548800,
                "headline": "Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology"
              },
              {
                "id": 140958478,
                "url": "https://finnhub.io/api/news?id=cc6ec253511baccbdfea5ad1f5f444625c032d12536f4b0d04339169e1be0d6d",
                "image": "https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "Incyte Corp (INCY) offers a compelling value opportunity with strong profitability, near-zero debt, and a P/E of 15.76—well below the biotech industry average of 36.43. Despite slowing growth forecasts, its low valuation provides a solid margin of safety.",
                "category": "company",
                "datetime": 1784546426,
                "headline": "Incyte Corp (NASDAQ:INCY) Shows Value Stock Strength With Strong Fundamentals and Low Valuation"
              },
              {
                "id": 140965151,
                "url": "https://finnhub.io/api/news?id=6e09676ee2faf44c563ffb6d43432f0a928562e1a85e9fbc345546cf2b476777",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Halozyme Therapeutics, Inc. (NASDAQ:HALO) (&#34;Halozyme&#34; or the &#34;Company&#34;) today announced that it has entered into a global collaboration and license agreement with Incyte (NASDAQ:INCY) to evaluate",
                "category": "company",
                "datetime": 1784534503,
                "headline": "Halozyme Therapeutics Signs Agreement With Incyte To Mull Additional Subcutaneous Formulations Of INCA033989 Mutant Calreticulin-Targeted Monoclonal Antibody"
              },
              {
                "id": 140955778,
                "url": "https://finnhub.io/api/news?id=989fbbfabc0bbae37e46ab4bb57fb1e7723b8234cb8ccda6eb5366a42f05e17e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2285994413/image_2285994413.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Xencor (XNCR) stays a Strong Buy as XmAb819 and XmAb942 advance; key data due 2026–2027 and $542M cash extends runway—read the outlook now.",
                "category": "company",
                "datetime": 1784493770,
                "headline": "Xencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim Data"
              },
              {
                "id": 140934672,
                "url": "https://finnhub.io/api/news?id=87e27eb69603b6ccc7a6a57a2d4741fe9b7d8c1349d5a887b8c1f5ef9659d186",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "WILMINGTON, Del., July 17, 2026--Incyte Data to Be Highlighted in Four Rapid Oral Presentations at ESMO 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers",
                "category": "company",
                "datetime": 1784308200,
                "headline": "Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers"
              },
              {
                "id": 140935749,
                "url": "https://finnhub.io/api/news?id=bea42c5120469a8c954f17659495dd562c8902c0244836e35eb6837eb95f7ee1",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1196320934/image_1196320934.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte Corporation is a profitable, cash-generating biotech with a robust pipeline and a core revenue driver in Jakafi. Read more on INCY stock here.",
                "category": "company",
                "datetime": 1784301703,
                "headline": "Incyte: Profitable Biotech That Could Be Close To Exploding"
              },
              {
                "id": 140937696,
                "url": "https://finnhub.io/api/news?id=a553b39a41af82b706247ec18aa19d8ef3e0571d48245853b03dd7a9bbf8d0b5",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a",
                "category": "company",
                "datetime": 1784293970,
                "headline": "Incyte To Present New Phase 1 Solid Tumor Data, Including KRAS G12D and TGFβR2×PD‑1 Programs, At ESMO 2026"
              },
              {
                "id": 140925108,
                "url": "https://finnhub.io/api/news?id=05939657d6c850e1eebf82da32b184016550b8b3393b7ffd86aea3de083daf7d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1285391908/image_1285391908.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Steven Cress, Seeking Alpha's Head of Quant, provides his top 2 stocks for H2 2026.",
                "category": "company",
                "datetime": 1784220120,
                "headline": "Steven Cress' Top 2 Stocks H2 2026"
              },
              {
                "id": 140919919,
                "url": "https://finnhub.io/api/news?id=ac38e40815783f8ec5171d72b4c86aa0d5496672e10888f4bb0f5347b866864d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.",
                "category": "company",
                "datetime": 1784207177,
                "headline": "Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside"
              },
              {
                "id": 140917605,
                "url": "https://finnhub.io/api/news?id=9b0419b4f5188dcfa8be73ee7427bd5e72acdec1e9a88099cd671cf7f6b7d196",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte is scheduled to release its second-quarter results later this month, with analysts projecting a double-digit increase in its bottom line figure.",
                "category": "company",
                "datetime": 1784164726,
                "headline": "What to Expect From Incyte's Q2 2026 Earnings Report"
              },
              {
                "id": 140911616,
                "url": "https://finnhub.io/api/news?id=a21356dd71ba4a29f749ef6a9402b694ac4b5f7bec9fd511f75b6d42947c718e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 8.6% to $114.25 per share while the index has gained 8.2%.",
                "category": "company",
                "datetime": 1784133437,
                "headline": "Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings?"
              },
              {
                "id": 140902248,
                "url": "https://finnhub.io/api/news?id=40bf04d5730d9953faaebb0f7710b06678dc230e6d9574421efc3f181641f562",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2250479883/image_2250479883.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Syndax Pharma outlook: Revuforj first-mover edge, pipeline catalysts (Niktimvo), and profitability path amid misses. Click here to read more about SNDX.",
                "category": "company",
                "datetime": 1784047680,
                "headline": "A Fresh Look At Syndax Pharmaceuticals"
              },
              {
                "id": 140898821,
                "url": "https://finnhub.io/api/news?id=915e96bee8a935b573658cd266498a4469639874ea9e63198fef5e4fae5c3427",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Barclays  analyst Etzer Darout   maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $117 to $134.",
                "category": "company",
                "datetime": 1784012695,
                "headline": "Barclays Maintains Overweight on Incyte, Raises Price Target to $134"
              },
              {
                "id": 140890161,
                "url": "https://finnhub.io/api/news?id=e25110c78ca2177615e41497f4272b141937d60a5e1b269003abf9d7270f7d7c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.2% and",
                "category": "company",
                "datetime": 1783971281,
                "headline": "Sector Update: Healthcare Stocks Advance Late Afternoon"
              },
              {
                "id": 140888428,
                "url": "https://finnhub.io/api/news?id=ed15eb87356bea39d17c294679a13f32dbb5cc7c416f7aa1579ca7722654403b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.",
                "category": "company",
                "datetime": 1783964231,
                "headline": "Own Regeneron For Biotech Growth? Incyte Is Making Its Case."
              },
              {
                "id": 140888631,
                "url": "https://finnhub.io/api/news?id=f141f5f93afa2376a17eccdb81a87ce04b3a142187092e639c75235d6edf9843",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) is back in focus after releasing complete safety and efficacy data from a Phase 1/2 study of latarcibart, its investigational monoclonal antibody for von Willebrand disease, and advancing the program into Phase 3. See our latest analysis for Incyte. Against this backdrop, Incyte’s shares have been firming, with a 30 day share price return of 7.54% and a 90 day share price return of 19.47%, while the 1 year total shareholder return of 66.78% points to strong longer term momentum...",
                "category": "company",
                "datetime": 1783962522,
                "headline": "Incyte (INCY) Could Be 8% Overvalued As Latarcibart Moves Into Phase 3"
              },
              {
                "id": 140887161,
                "url": "https://finnhub.io/api/news?id=aed32e5440335247d1d54e1a848e0f60f7f66ffd9371a9b6a69f6d8f58de61e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte recently reported full Phase 1/2 multidose data for latarcibart (VGA039), an investigational, once‑monthly subcutaneous monoclonal antibody that targets Protein S and showed substantial reductions in bleeding rates across all von Willebrand disease types, with a favorable safety profile, in 16 treated patients. The therapy’s potential to offer the first self‑administered, once‑monthly prophylactic option for VWD, versus frequent intravenous factor infusions, could materially change...",
                "category": "company",
                "datetime": 1783955436,
                "headline": "How Investors May Respond To Incyte (INCY) Latarcibart Data In Von Willebrand Disease Prophylaxis"
              },
              {
                "id": 140887162,
                "url": "https://finnhub.io/api/news?id=a54ac809d7cdb682cc8a30ea6b1cc5e4ce52c4dcab3da92267c40898fb12ac33",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte Corporation (NASDAQ:INCY) on Monday reported complete Phase 1/2 multidose data for latarcibart (VGA039), showing substantial reductions in bleeding episodes and a favorable safety profile in patients with von Willebrand disease (VWD). VWD is the most common inherited bleeding disorder, affecting about 1% of the population. It is caused by a deficiency or malfunction of the von Willebrand factor, a blood protein needed for platelets to clot properly. Read Also: Incyte Bets $1.25 Billion On",
                "category": "company",
                "datetime": 1783949108,
                "headline": "Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder"
              },
              {
                "id": 140886052,
                "url": "https://finnhub.io/api/news?id=a487fe79641a5675cdde5b8921f6b47577015aee11c289601fe16b2ede882a21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks fared in Q1, starting with Incyte (NASDAQ:INCY).",
                "category": "company",
                "datetime": 1783945839,
                "headline": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks"
              },
              {
                "id": 140887931,
                "url": "https://finnhub.io/api/news?id=e7bc2ada588cf2adac84f1c0501fa0221bd7ce5aaec251bb11ce57714a088ce5",
                "image": "https://image.cnbcfm.com/api/v1/image/108331043-1783365848624-gettyimages-2280068333-sc1_1154_pvccmh9y.jpeg?v=1783365884&w=1920&h=1080",
                "source": "CNBC",
                "related": "INCY",
                "summary": "Economy is one of the most important categories in CNBC’s annual America’s Top States for Business rankings. Several states stand out for economic strength.",
                "category": "company",
                "datetime": 1783936801,
                "headline": "The 10 best state economies in America in 2026"
              },
              {
                "id": 140887877,
                "url": "https://finnhub.io/api/news?id=cdbb5549ed0b6511090695ecb351e10424f0d4e6f46e9305e90cc729adbbc3b3",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "BMO Capital  analyst Evan Seigerman   maintains Incyte (NASDAQ:INCY) with a Market Perform and raises the price target from $94 to $112.",
                "category": "company",
                "datetime": 1783933048,
                "headline": "BMO Capital Maintains Market Perform on Incyte, Raises Price Target to $112"
              },
              {
                "id": 140883892,
                "url": "https://finnhub.io/api/news?id=e514bb5e9f92d121de0f4c7a453af020ffe4125b9dd18482ef5eed90ce7c69d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "WILMINGTON, Del., July 13, 2026--Phase 1/2 Multidose Data for VGA039 (Latarcibart) Show Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types",
                "category": "company",
                "datetime": 1783929600,
                "headline": "Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types"
              },
              {
                "id": 140856160,
                "url": "https://finnhub.io/api/news?id=f876d79aaa0f42fdd94092d76f6a95c9aa9d7384368c9d05ba671d9e973b0e50",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195840496/image_2195840496.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Seeking Alpha's Head of Quant, Steve Cress, provides a mid-year update on his top 10 stocks for 2026.",
                "category": "company",
                "datetime": 1783622040,
                "headline": "Steven Cress' Top 10 Stocks For 2026 (Mid-Year Review)"
              },
              {
                "id": 140846990,
                "url": "https://finnhub.io/api/news?id=69f5b1271559deaac456457fd86796529813269ee230961a08b70f458add660c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.",
                "category": "company",
                "datetime": 1783556700,
                "headline": "2 Fast-Growing Pharmaceutical Stocks to Buy Now"
              },
              {
                "id": 140843654,
                "url": "https://finnhub.io/api/news?id=9d1002029bc82808b25ccb335642eb3cc1cc4ba8647e4508fc48b73a0d083390",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1314804423/image_1314804423.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Jonathan Faison, who runs ROTY biotech community, shares why much of the current euphoria in biotech is driven by fundamentals.",
                "category": "company",
                "datetime": 1783519200,
                "headline": "Biotech Euphoria Driven By Fundamentals"
              },
              {
                "id": 140840573,
                "url": "https://finnhub.io/api/news?id=5e139a297017ff79fead3a17df77dd2984859059085fd34751ce71e2a30a986a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.",
                "category": "company",
                "datetime": 1783514909,
                "headline": "Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside"
              },
              {
                "id": 140840730,
                "url": "https://finnhub.io/api/news?id=fb64b0659f3223fcb2bf9e7a59579554e2b2943853a21329479369a2c1004907",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "WILMINGTON, Del., July 08, 2026--Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026.",
                "category": "company",
                "datetime": 1783512000,
                "headline": "Incyte to Report Second Quarter Financial Results"
              },
              {
                "id": 140834756,
                "url": "https://finnhub.io/api/news?id=dc3cf7f4fad94fb261d230d6d8782221966701b25c4009d4f60cd68acc524703",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $95 to $99.",
                "category": "company",
                "datetime": 1783424452,
                "headline": "RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $99"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 84,
            "discarded_article_count": 61
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17.8,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.7,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.7,
            "vcp_reason": "波幅收縮(23.7%→15.3%)；跌縮量(近10日3日)；站上MA50；升放量(近10日3日)；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 1956533.3333333333,
              "down_days": 5,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 2347270,
              "avg_vol_20": 1928805,
              "avg_vol_30": 1956533.3333333333,
              "range_pct_10": 0.15281305963845238,
              "range_pct_20": 0.1861801824632539,
              "range_pct_30": 0.23745573576617676,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 3,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.1997086683930762,
              "dist_to_20d_high": 0.10723988633183362,
              "down_shrink_days": 3,
              "breakout_level_20d": 132.60001,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.6435433498600672
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "較差",
        "items": {
          "position": {
            "score": 1.3,
            "details": {
              "atrPct": 3.8761615137692176,
              "turnoverUsdM": 282.96525293999997,
              "liquidityPoints": 0.6,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.INCY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 109.2028,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 2,
              "macd_score": 1.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 7.8,
            "take_profit_price": 127.8249,
            "target_multiplier": 1.9,
            "technical_strength": 1.63,
            "take_profit_percent": 8
          },
          "positionPoints": 1.3,
          "stopLossPoints": 1.2,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 7.752323027538435,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.INCY",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 4.5886,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.88
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -14.67
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.011
    },
    "kdj": {
      "d": 39.14,
      "j": 2.98,
      "k": 27.09,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 62.45
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 4,
      "trend": "弱勢",
      "value": 7990687,
      "recentSlope": -224511.3,
      "previousSlope": 679600
    },
    "rsi": 51.62,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 130.0286,
      "position": "SAR喺價上",
      "distancePct": 9.84,
      "previousTrend": "下降"
    },
    "ma50": 110.9026,
    "macd": {
      "macd": 2.5295029105882065,
      "trend": "中性偏多",
      "signal": 3.198707644493195,
      "histogram": -0.6692047339049885
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 120.1706,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.21,
      "score": 6,
      "avgVolume": 1980641,
      "currentVolume": 2390313
    },
    "derived": {
      "ma20": 118.681,
      "ma50": 110.9026,
      "prevClose": 119.8,
      "avgVolume10": 2490681,
      "avgVolume20": 1980641,
      "changePercent": -1.19,
      "avgVolumeForScore": 1980641
    },
    "ma_cross": {
      "ma20": 118.681,
      "ma50": 110.9026,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 118.688,
      "prevMa50": 110.477,
      "spreadPct": 7.01,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 110.8935,
      "upper": 126.4685,
      "position": "中間"
    },
    "rsi_short": 16.62,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.21
    }
  }
}

Raw metrics JSON

 
{
  "close": 118.38,
  "volume": 2390313,
  "changePercent": -1.19
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.